How Young Is Too Young for GLP-1 Meds?

GLP-1 medications such as Wegovy and Zepbound have reshaped obesity treatment for adults and are increasingly being used to help adolescents with obesity. Now, a more challenging question is taking center stage: Should these medications be used in even younger children?
While the U.S. Food and Drug Administration (FDA) has approved some GLP-1 medications for adolescents ages 12 and older who meet specific criteria, a small but growing number of physicians are prescribing them off-label for elementary school-age children with severe obesity. The trend has sparked debate among healthcare providers, researchers, and parents over whether early intervention outweighs the unknown long-term risks.
Not all GLP-1 medications are approved for pediatric obesity treatment, and those that are have age restrictions. Wegovy, for example, is approved for chronic weight management in adolescents aged 12 and older who have obesity and meet certain medical requirements.
Doctors generally reserve these medications for children whose obesity has not improved despite comprehensive lifestyle interventions, including healthier eating habits, increased physical activity, and behavioral support.
The medications are not intended for children who simply want to lose weight. Instead, they are considered for young people with obesity who face increased risks for serious health conditions such as type 2 diabetes, high blood pressure, fatty liver disease, and cardiovascular disease.
Many obesity specialists argue that treating obesity early may prevent lifelong health complications. Clinical trials have shown that GLP-1 medications can produce significant weight loss in adolescents when combined with lifestyle changes. Physicians who support their use view obesity as a chronic disease that often requires medical treatment alongside healthy habits.
For some children with severe obesity, waiting until adulthood may allow health problems to progress. Dr. Jessica Reilly, medical director of the Strong4Life pediatric obesity clinic at Children’s Healthcare of Atlanta, sees the consequences firsthand:
I see kids who have developed Type 2 diabetes at 10, 11 years old… They need help so desperately.
Although GLP-1 medications are approved for obesity beginning at age 12, some physicians are prescribing them off-label for children as young as six. One widely reported example involves nine-year-old twins Ayden and Kayden Gatlin-Wright. After years of unsuccessful efforts with diet, exercise, and nutritional counseling, doctors discovered the brothers carried a genetic mutation that affects feelings of fullness and increases their risk of obesity.
Despite working closely with healthcare professionals, their body mass index (BMI) continued to rise, and by age seven, they showed elevated blood sugar levels, abnormal cholesterol, and signs of liver dysfunction.
Their parents decided to pursue off-label treatment with Wegovy, paying approximately $700 every four weeks out of pocket for both children.
The medication appears to be helping. According to reports, Ayden’s BMI has declined by about 5%, while Kayden’s has fallen by roughly 7%. Beyond the numbers, their parents say the boys are developing healthier habits and enjoying more energy.
Despite encouraging early results, many pediatric experts urge caution. One of the biggest concerns is the lack of long-term research on children who might remain on these medications for many years — or even decades.
Questions remain about:
- How long children may need to stay on GLP-1 medications
- Whether weight returns after treatment stops
- The effects of long-term use on growth and development
- Potential nutritional deficiencies if children eat significantly less
- Whether medication could unintentionally replace healthy lifestyle habits
Common side effects include nausea, vomiting, diarrhea, and other gastrointestinal symptoms. Although uncommon, more serious complications can include pancreatitis and gallbladder disease.
Dr. Sarah Hampl, who works in the pediatric obesity program at Children’s Mercy Hospital in Kansas City, believes more research is needed before expanding treatment to younger children. She said:
We do not have enough evidence to safely prescribe under 12 at this point… I think that potential is there for positive impact, but there are not enough studies yet.
Drug manufacturers are also proceeding cautiously. Novo Nordisk, the maker of Wegovy, does not promote off-label prescribing, although it is studying the medication in children as young as six. Eli Lilly is conducting similar research with Zepbound.
Even among families who have seen success with GLP-1 medications, the goal is not lifelong dependence on the drugs. The parents of Ayden and Kayden hope the medication will provide a window of opportunity for their sons to establish sustainable habits that last well beyond treatment. As their father explained:
They can learn to manage themselves, the exercise, the healthy habits, read their bodies properly. The goal is for them to learn that, you know, as they grow, this is going to be their life.
This perspective reflects the broader approach recommended by obesity specialists, who generally view medication as one part of a comprehensive treatment plan that includes nutrition, physical activity, behavioral counseling, and family support.
Even for patients who qualify, obtaining GLP-1 medications can be difficult because of cost and insurance coverage. To improve access for eligible older adults, Medicare launched the temporary GLP-1 Bridge Program on July 1. The program allows qualifying Medicare Part D beneficiaries to receive eligible weight-loss medications, including Wegovy and certain formulations of Zepbound, for a $50 monthly copay while broader coverage policies continue to evolve.
Families with younger children, however, often face significant financial barriers. Off-label prescriptions are frequently not covered by insurance, leaving parents responsible for hundreds of dollars each month.
For now, experts remain divided. While some see early treatment as an opportunity to prevent serious disease, others believe the science has not yet caught up with the growing interest in prescribing these medications to children under 12.
Your responses and feedback are welcome!
Source: “Fact Check Team: How young is too young for GLP-1 medications?,” The National News Desk, 7/10/26
Source: “Kids as young as six are being given weight-loss drugs as a way to curb obesity before it gets too late,” The Independent, 06/22/26
Image by Tima Miroshnichenko/Pexels









FAQs and Media Requests: